Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

March 09, 2017

News Conference News ACC 2016

DANAMI3: Deferred Stenting, Ischemic Postconditioning No Help in STEMI

April 04, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.